Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
recombinant respiratory syncytial virus vaccine (CHO cells)
- Development stage
- Phase 1
- Lead developer
- WANTAI BioPharm
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Intramuscular
01
Overview
The recombinant respiratory syncytial virus vaccine (CHO cells) is a protein subunit vaccine developed by Xiamen Wan Tai (Beijing Wantai Biological Pharmacy) for the prevention of respiratory syncytial virus (RSV) infection. The vaccine is composed of the RSV fusion (F) protein, which is a key surface glycoprotein responsible for viral entry and a primary target for neutralizing antibodies. This antigen is produced using a Chinese Hamster Ovary (CHO) cell expression system, a standard platform for complex recombinant proteins. By administering the recombinant F protein, the vaccine aims to elicit a robust immune response, specifically inducing neutralizing antibodies that prevent the virus from infecting host cells. As of March 2026, the candidate has received Investigational New Drug (IND) approval and is in Phase 1 clinical development.
- Other names
- RSV F protein vaccinerecombinant respiratory syncytial virus vaccine (chinese hamster ovary cells)recombinant protein vaccine (CHO cell expression)RSV subunit vaccine
02
Targets
RSV F (Respiratory syncytial virus fusion protein)
Beyond the preview
Go deeper on recombinant respiratory syncytial virus vaccine (CHO cells).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on recombinant respiratory syncytial virus vaccine (CHO cells).